In preclinical models of diabetes, SGLT2 inhibition reduced hyperglycemia-induced oxidative stress and advanced glycation end products within proximal tubular cells and attenuated tubulointerstitial inflammation and fibrosis [5]. Here, SLC5A2 is linked to diabetes mellitus.